{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:40:46Z","timestamp":1786621246992,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nucmedbio.2026.109653","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:39:53Z","timestamp":1782455993000},"page":"109653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pretargeted imaging beyond the blood\u2013brain barrier: From concept to reality"],"prefix":"10.1016","volume":"158-159","author":[{"given":"Thomas Erik","family":"Wuensche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Stotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto Maria","family":"Battisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Manfred","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109653_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22187","article-title":"Unveiling the potential of antisense oligonucleotides: mechanisms, therapies, and safety insights","volume":"85","author":"Ers\u00f6z","year":"2024","journal-title":"Drug Dev Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1060028018789956","article-title":"Nusinersen: a treatment for spinal muscular atrophy","volume":"53","author":"Claborn","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109653_bb0020","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0025","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pharmtox-061724-080811","article-title":"How biologics have changed the drug discovery landscape","author":"Mcgonigle","year":"2025","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0030","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0040","article-title":"Donanemab for Alzheimer\u2019s disease: a systematic review of clinical trials","volume":"11","author":"Rashad","year":"2023","journal-title":"Healthcare (Switzerland)"},{"issue":"17","key":"10.1016\/j.nucmedbio.2026.109653_bb0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314450121","article-title":"Lecanemab blocks the effects of the A\u03b2\/fibrinogen complex on blood clots and synapse toxicity in organotypic culture","volume":"121","author":"Singh","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0050","doi-asserted-by":"crossref","DOI":"10.52965\/001c.31925","article-title":"Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer\u2019s disease: a comprehensive review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0055","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109653_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100204","article-title":"Drug delivery strategies to cross the blood-brain barrier in Alzheimer\u2019s disease: a comprehensive review on three promising strategies","volume":"12","author":"de Koning","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"January","key":"10.1016\/j.nucmedbio.2026.109653_bb0065","first-page":"1","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRX"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109653_bb0075","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0080","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109653_bb0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2967\/jnumed.118.220939","article-title":"Brain access of monoclonal antibodies as imaged and quantified by 89Zr-antibody PET: perspectives for treatment of brain diseases","volume":"60","author":"Veldhuijzen van Zanten","year":"2019","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109653_bb0090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.119.239558","article-title":"The role of 89Zr-immuno-pet in navigating and derisking the development of biopharmaceuticals","volume":"62","author":"Van Dongen","year":"2021","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109653_bb0095","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","article-title":"Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody","volume":"50","author":"Stergiou","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0100","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s11307-022-01744-y","article-title":"Non-invasive imaging of antisense oligonucleotides in the brain via in vivo click chemistry","volume":"24","author":"Cook","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"797","key":"10.1016\/j.nucmedbio.2026.109653_bb0105","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1126\/scitranslmed.adl1732","article-title":"PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry","volume":"17","author":"Cook","year":"2025","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.nucmedbio.2026.109653_bb0110","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1007\/s00259-019-04426-0","article-title":"MINC faculty. Engineered antibodies: new possibilities for brain PET?","volume":"46","author":"Sehlin","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer\u2019s disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.nucmedbio.2026.109653_bb0120","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.7150\/thno.73509","article-title":"Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody \u2013 the choice of chelator is essential","volume":"12","author":"Wuensche","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0125","series-title":"Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET","volume":"18","author":"Verel","year":"2003"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0130","series-title":"IEEE Nuclear Science Symposium Conference Record, 2005","first-page":"1624","article-title":"High resolution PET imaging characteristics of \/sup 68\/Ga, \/sup 124\/I and \/sup 89\/Zr compared to \/sup 18\/F","volume":"Vol 3","author":"de Jong","year":"2005"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108969","article-title":"New prospects for 89Zr-immuno-PET in brain applications \u2013 alpha-synucleinopathies","volume":"140-141","author":"Wuensche","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0140","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-024-01931-z","article-title":"Investigation of the impact of the H310A FcRn region mutation on 89Zr-immuno-PET brain imaging with a BBB-shuttle anti-amyloid beta antibody","author":"Wuensche","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0145","first-page":"2014","article-title":"124Iodine: a longer-life positron emitter isotope - new opportunities in molecular imaging","author":"Cascini","year":"2014","journal-title":"Biomed Res Int"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109653_bb0150","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.2967\/jnumed.109.065862","article-title":"Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients","volume":"50","author":"B\u00f6rjesson","year":"2009","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109653_bb0155","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2967\/jnumed.116.188037","article-title":"The use of microdosing in the development of small organic and protein therapeutics","volume":"58","author":"Bergstrom","year":"2017","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109653_bb0160","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","article-title":"Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies","volume":"40","author":"Zanotti-Fregonara","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0165","article-title":"A cutting-edge technology for the future of nuclear medicine","volume":"11","author":"Glaudemans","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0170","article-title":"Total body PET\/CT: future aspects","author":"Godinez","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"24","key":"10.1016\/j.nucmedbio.2026.109653_bb0175","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1021\/acschemneuro.0c00652","article-title":"Fluorine-18-labeled antibody ligands for PET imaging of amyloid-\u03b2 in brain","volume":"11","author":"Syv\u00e4nen","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0180","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.5c00359","article-title":"Fluorine-18 ImmunoPET imaging of antibody brain kinetics and amyloid-beta pathology","author":"Schlein","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bdd.2338","article-title":"Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: advances, challenges, and future perspectives","volume":"44","author":"Goto","year":"2023","journal-title":"Biopharm Drug Dispos"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109653_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101191","article-title":"Pretargeted Imaging beyond the blood\u2013brain barrier\u2014utopia or feasible?","volume":"15","author":"Lopes van den Broek","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0195","first-page":"141","article-title":"Transport of nanomedicines across the blood-brain barrier: challenges and opportunities for imaging and therapy","author":"van den Broek","year":"2022","journal-title":"Biomater Adv"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.biomaterials.2018.06.021","article-title":"Pretargeting in nuclear imaging and radionuclide therapy: improving efficacy of theranostics and nanomedicines","volume":"179","author":"St\u00e9en","year":"2018","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0205","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/ph15060685","article-title":"Recent advances in the development of tetrazine ligation tools for pretargeted nuclear imaging","volume":"15","author":"Garc\u00eda-V\u00e1zquez","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0210","first-page":"108","article-title":"In vivo-stable bis-iminobiotin for targeted radionuclide delivery with the mutant streptavidin","author":"Tatsumi","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109653_bb0215","first-page":"1284","article-title":"In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy","volume":"44","author":"Lewis","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0220","first-page":"381","article-title":"Optimizing peptide nucleic acid-based pretargeting for enhanced targeted radionuclide therapy","author":"Altai","year":"2025","journal-title":"J Control Release"},{"issue":"5876","key":"10.1016\/j.nucmedbio.2026.109653_bb0225","first-page":"664","article-title":"In vivo imaging of membrane-associated glycans in developing zebrafish","volume":"320","author":"Laughlin","year":"2008","journal-title":"Science (1979)"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109653_bb0230","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2967\/jnumed.122.265008","article-title":"Pretargeting with cucurbituril\u2013adamantane host\u2013guest pair in xenograft models","volume":"64","author":"Jallinoja","year":"2023","journal-title":"J Nucl Med"},{"issue":"40","key":"10.1016\/j.nucmedbio.2026.109653_bb0235","doi-asserted-by":"crossref","first-page":"10549","DOI":"10.1002\/anie.201304026","article-title":"Mesoporous silica nanoparticle pretargeting for PET imaging based on a rapid bioorthogonal reaction in a living body","volume":"52","author":"Lee","year":"2013","journal-title":"Angew Chem Int Ed"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109653_bb0240","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1021\/acs.bioconjchem.2c00164","article-title":"Pretargeted PET imaging with a TCO-conjugated anti-CD44v6 chimeric mAb U36 and [89Zr]Zr-DFO-PEG5-Tz","volume":"33","author":"Lumen","year":"2022","journal-title":"Bioconjug Chem"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109653_bb0245","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1021\/acs.molpharmaceut.5b00294","article-title":"Optimization of a pretargeted strategy for the PET imaging of colorectal carcinoma via the modulation of radioligand pharmacokinetics HHS public access","volume":"12","author":"Zeglis","year":"2015","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0250","doi-asserted-by":"crossref","first-page":"887","DOI":"10.7150\/thno.14742","article-title":"Conformationally strained trans-cyclooctene (sTCO) enables the rapid construction of 18F-PET probes via tetrazine ligation","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109653_bb0255","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/acs.bioconjchem.5b00504","article-title":"18F-based pretargeted PET imaging based on bioorthogonal Diels-Alder click chemistry","volume":"27","author":"Meyer","year":"2016","journal-title":"Bioconjug Chem"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109653_bb0260","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2967\/jnumed.117.189944","article-title":"Pretargeted imaging and therapy","volume":"58","author":"Altai","year":"2017","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109653_bb0265","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: a path forward for radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109653_bb0270","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1021\/acs.chemrev.0c00928","article-title":"A hitchhiker\u2019s guide to click-chemistry with nucleic acids","volume":"121","author":"Fantoni","year":"2021","journal-title":"Chem Rev"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0275","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/acs.bioconjchem.4c00084","article-title":"Click chemistry: reaction rates and their suitability for biomedical applications","volume":"35","author":"Luu","year":"2024","journal-title":"Bioconjug Chem"},{"issue":"20","key":"10.1016\/j.nucmedbio.2026.109653_bb0280","article-title":"In vivo applications of bioorthogonal reactions: chemistry and targeting mechanisms","volume":"29","author":"Mitry","year":"2023","journal-title":"Chem Eur J"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0285","series-title":"Bioorthogonal chemistry: implications for pretargeted nuclear (PET\/SPECT) imaging and therapy","volume":"Vol 4","author":"Knight","year":"2014"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109653_bb0290","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1021\/acs.bioconjchem.3c00286","article-title":"Click chemistry and radiochemistry: an update","volume":"34","author":"Bauer","year":"2023","journal-title":"Bioconjug Chem"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109653_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.preme.2025.100035","article-title":"Host\u2013guest architectures: advancing pretargeting strategies for precision theranostics","volume":"2","author":"Gan","year":"2025","journal-title":"Precision Medicine and Engineering"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109653_bb0300","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acsptsci.1c00007","article-title":"Lipophilicity and click reactivity determine the performance of bioorthogonal tetrazine tools in pretargeted in vivo chemistry","volume":"4","author":"St\u00e9en","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109653_bb0305","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1039\/D2MD00360K","article-title":"Pretargeted imaging beyond the blood-brain barrier","volume":"14","author":"Shalgunov","year":"2022","journal-title":"RSC Med Chem"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s43586-021-00028-z","article-title":"Bioorthogonal chemistry","volume":"1","author":"Scinto","year":"2021","journal-title":"Nat Rev Methods Primers"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-024-00275-x","article-title":"Trans-cyclooctene\u2014a Swiss army knife for bioorthogonal chemistry: exploring the synthesis, reactivity, and applications in biomedical breakthroughs","volume":"9","author":"Adhikari","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109653_bb0320","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1021\/bc400153y","article-title":"Highly reactive trans -cyclooctene tags with improved stability for Diels\u2013Alder chemistry in living systems","volume":"24","author":"Rossin","year":"2013","journal-title":"Bioconjug Chem"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109653_bb0325","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1021\/acs.bioconjchem.8b00385","article-title":"Dendrimer scaffold for the amplification of in vivo pretargeting ligations","volume":"29","author":"Cook","year":"2018","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0330","first-page":"14","article-title":"Key considerations based on pharmacokinetic\/pharmacodynamic in the design of antibody-drug conjugates","author":"Gao","year":"2024","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109653_bb0335","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109653_bb0340","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/acs.molpharmaceut.5c01802","article-title":"In vivo comparison of site-specific and site-selective methods for pretargeted imaging in a murine model of colorectal cancer","volume":"23","author":"Zabrocki","year":"2026","journal-title":"Mol Pharm"},{"issue":"35","key":"10.1016\/j.nucmedbio.2026.109653_bb0345","doi-asserted-by":"crossref","first-page":"11668","DOI":"10.1039\/D1SC02789A","article-title":"Direct cu-mediated aromatic 18F-labeling of highly reactive tetrazines for pretargeted bioorthogonal PET imaging","volume":"12","author":"Garc\u00eda-V\u00e1zquez","year":"2021","journal-title":"Chem Sci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s44303-025-00087-x","article-title":"Copper-mediated radiochemistry: historical impact, current trends, and future possibilities","volume":"3","author":"Bowden","year":"2025","journal-title":"npj Imaging"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109653_bb0355","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.bmcl.2019.02.014","article-title":"Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging","volume":"29","author":"St\u00e9en","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"36","key":"10.1016\/j.nucmedbio.2026.109653_bb0360","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/anie.201404277","article-title":"Development of a 18F-labeled tetrazine with favorable pharmacokinetics for bioorthogonal PET imaging","volume":"53","author":"Denk","year":"2014","journal-title":"Angew Chem Int Ed"},{"issue":"10","key":"10.1016\/j.nucmedbio.2026.109653_bb0365","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1021\/acs.bioconjchem.3c00385","article-title":"Evaluation of tetrazine tracers for pretargeted imaging within the central nervous system","volume":"34","author":"Edelmann","year":"2023","journal-title":"Bioconjug Chem"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109653_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121445","article-title":"Antibody-based in vivo imaging of central nervous system targets\u2014evaluation of a pretargeting approach utilizing a TCO-conjugated brain shuttle antibody and radiolabeled Tetrazines","volume":"15","author":"Bredack","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0375","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5c01180","article-title":"Pretargeted Immuno-PET enables monoclonal antibody imaging beyond the blood\u2013brain barrier","author":"Gustavsson","year":"2025","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0380","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-024-00250-6","article-title":"Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET","volume":"9","author":"Schlein","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0385","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40035-025-00532-2","article-title":"Pretargeted brain PET imaging reveals amyloid-\u03b2 pathology using a TCO-modified antibody and a fluorine-18-labeled tetrazine","volume":"14","author":"Lopes van den Broek","year":"2025","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0390","first-page":"128","article-title":"Evaluation of F-537-Tetrazine in a model for brain pretargeting imaging. Comparison to N-(3-[18F] fluoro-5- (1,2,4,5-tetrazin-3-yl)benzyl)propan-1-amine","author":"Shalgunov","year":"2024","journal-title":"Nucl Med Biol"},{"issue":"41","key":"10.1016\/j.nucmedbio.2026.109653_bb0395","doi-asserted-by":"crossref","first-page":"38252","DOI":"10.1021\/acsomega.3c04597","article-title":"Characterization of structurally diverse 18F-labeled d-TCO derivatives as a PET probe for bioorthogonal pretargeted imaging","volume":"8","author":"Adhikari","year":"2023","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0400","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.nucmedbio.2014.03.023","article-title":"In vivo evaluation of 18F-labeled TCO for pre-targeted PET imaging in the brain","volume":"41","author":"Wyffels","year":"2014","journal-title":"Nucl Med Biol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109653_bb0405","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1021\/acsomega.9b03584","article-title":"Preclinical evaluation of a novel 18f-labeled dtco-amide derivative for bioorthogonal pretargeted positron emission tomography imaging","volume":"5","author":"Ruivo","year":"2020","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109653_bb0410","article-title":"Toward realization of bioorthogonal chemistry in the clinic","volume":"383","author":"de Roode","year":"2025","journal-title":"Top Curr Chem"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109653_bb0415","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acs.bioconjchem.2c00583","article-title":"Recent advances in bioorthogonal click chemistry for enhanced PET and SPECT radiochemistry","volume":"34","author":"Zhong","year":"2023","journal-title":"Bioconjug Chem"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109653_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081164","article-title":"Central nervous system targeted protein degraders","volume":"13","author":"Thomas","year":"2023","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109653_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox9090861","article-title":"Pet imaging for oxidative stress in neurodegenerative disorders associated with mitochondrial dysfunction","volume":"9","author":"Ikawa","year":"2020","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109653_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13061029","article-title":"PET imaging of neuro-inflammation with tracers targeting the translocator protein (TSPO), a systematic review: from bench to bedside","volume":"13","author":"Corica","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1380561","article-title":"SV2A PET imaging in human neurodegenerative diseases","volume":"16","author":"Bavarsad","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109653_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090847","article-title":"Alpha-Synuclein PET tracer development-an overview about current efforts","volume":"14","author":"Korat","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"S2","key":"10.1016\/j.nucmedbio.2026.109653_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/alz.083411","article-title":"Discovery and preclinical development of [18 F]ACI\u201019626, a first\u2010in\u2010class TDP\u201043 PET tracer","volume":"20","author":"Seredenina","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109653_bb0450","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"67","key":"10.1016\/j.nucmedbio.2026.109653_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202403446","article-title":"Comparison of different organometallics towards electrophilic aromatic 211At-astatinations of highly reactive tetrazines","volume":"30","author":"Poulie","year":"2024","journal-title":"Chem Eur J"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0460","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acs.bioconjchem.5b00609","article-title":"125I-tetrazines and inverse-electron-demand diels-alder chemistry: a convenient radioiodination strategy for biomolecule labeling, screening, and biodistribution studies","volume":"27","author":"Albu","year":"2016","journal-title":"Bioconjug Chem"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109653_bb0465","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2967\/jnumed.120.260687","article-title":"Current landscape in clinical pretargeted radioimmunoimaging and therapy","volume":"62","author":"Jallinoja","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109653_bb0470","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-27696-1","article-title":"A simplified, robust protocol for [18F]fluoride elution under mild conditions to enhance late-stage aromatic radiofluorinations","volume":"15","author":"Milton","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2026.109653_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.zemedi.2026.04.004","article-title":"Applications of artificial intelligence in nuclear medicine","author":"Kaiser","year":"2026","journal-title":"Z Med Phys"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109653_bb0480","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1021\/acschemneuro.2c00269","article-title":"In silico approaches for addressing challenges in CNS radiopharmaceutical design","volume":"13","author":"Jackson","year":"2022","journal-title":"ACS Chem Neurosci"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:25:36Z","timestamp":1786620336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":96,"alternative-id":["S0969805126000521"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109653","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretargeted imaging beyond the blood\u2013brain barrier: From concept to reality","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109653"}}